RestorGenex Corp. (NASDAQ:DFFN) Scheduled to Post Quarterly Earnings on Monday
RestorGenex Corp. (NASDAQ DFFN) traded up 2.5798% during mid-day trading on Monday, reaching $1.7138. The company’s stock had a trading volume of 4,544 shares. The company’s 50-day moving average price is $2.24 and its 200 day moving average price is $3.04. The firm’s market capitalization is $17.73 million. RestorGenex Corp. has a 52 week low of $1.68 and a 52 week high of $26.00.
COPYRIGHT VIOLATION NOTICE: This story was reported by American Banking News and is owned by of American Banking News. If you are accessing this story on another domain, it was illegally stolen and republished in violation of international trademark & copyright legislation. The original version of this story can be viewed at https://www.americanbankingnews.com/2017/08/07/restorgenex-corp-nasdaqdffn-scheduled-to-post-quarterly-earnings-on-monday.html.
RestorGenex Corp. Company Profile
Diffusion Pharmaceuticals Inc, formerly RestorGenex Corporation, is a clinical-stage biotechnology company. The Company is focused on developing standard-of-care treatments, including radiation therapy and chemotherapy. The Company’s lead product candidate, transcrocetinate sodium, also known as trans sodium crocetinate (TSC) is used in various cancer types, in which tumor oxygen deprivation (hypoxia) is known to diminish the effectiveness of treatments.
Receive News & Ratings for RestorGenex Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RestorGenex Corp. and related companies with MarketBeat.com's FREE daily email newsletter.